Skip to main content
Midas Edge

Harmony Biosciences Holdings, Inc.

For the period ended Sep 30, 2026. Filed Nov 4, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 4, 2026

HRMY$33.55-0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except share and per share data)

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · other · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · paid-in · ​ · comprehensive · ​ · Retained · ​ · stockholders’
​ · ​ ​ · Shares · ​ ​ · Amount · ​ ​ · capital · ​ ​ · loss · ​ ​ · earnings · ​ ​ · equity
Balance as of June 30, 2026​58,120,695​$1​$731,147​$(727)​$268,822​$999,243
Net income—​—​—​​—​48,196​48,196
Unrealized loss on investments​—​​—​​—​​(1,213)​​—​​(1,213)
Restricted stock unit tax withholding, net of stock option exercises599,386​—​17,960​​—​—​17,960
Stock-based compensation—​—​8,046​​—​—​8,046
Balance as of September 30, 202658,720,081​$1​$757,153​$(1,940)​$317,018​$1,072,232
​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · other · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · paid-in · ​ · comprehensive · ​ · Retained · ​ · stockholders’
​ · ​ ​ · Shares · ​ ​ · Amount · ​ ​ · capital · ​ ​ · income (loss) · ​ ​ · earnings · ​ ​ · equity
Balance as of December 31, 202557,726,170​$1​$708,968​$346​$160,903​$870,218
Net income—​—​—​​—​156,115​156,115
Unrealized loss on investments​—​​—​​—​​(2,286)​​—​​(2,286)
Restricted stock unit tax withholding, net of stock option exercises993,911​—​20,184​​—​—​20,184
Stock-based compensation—​—​28,001​​—​—​28,001
Balance as of September 30, 202658,720,081​$1​$757,153​$(1,940)​$317,018​$1,072,232
​​​​​​​​​​​​​​​​​​
​ · ​ ​ ​ · ​ · ​ ​ ​ · ​ · ​ · ​ ​ ​ · ​ · ​ · ​ · Accumulated · ​ ​ ​ · ​ · ​ · ​ ​ ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · other · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · paid-in · ​ · comprehensive · ​ · Accumulated · ​ · stockholders’
​ · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · capital · ​ · income · ​ ​ ​ · deficit · ​ ​ ​ · equity
Balance as of June 30, 202557,531,080​$1​$685,288​$239​$87,552​$773,080
Net income—​—​—​​—​50,865​50,865
Unrealized loss on investments​—​​—​​—​​118​​—​​118
Restricted stock unit tax withholding, net of stock option exercises65,278​—​91​​—​—​91
Stock-based compensation—​—​10,969​​—​—​10,969
Balance as of September 30, 202557,596,358​$1​$696,348​$357​$138,417​$835,123
​​​​​​​​​​​​​​​​​​
​ · ​ ​ ​ · ​ · ​ ​ ​ · ​ · ​ · ​ ​ ​ · ​ · ​ · ​ · Accumulated · ​ ​ ​ · ​ · ​ ​ ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · other · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · paid-in · ​ · comprehensive · ​ · Retained · ​ · stockholders’
​ · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · capital · ​ · income · ​ ​ ​ · earnings · ​ ​ ​ · equity
Balance as of December 31, 202457,144,887​$1​$656,872​$66​$2,216​$659,155
Net income—​—​—​​—​136,201​136,201
Unrealized gain on investments​—​​—​​—​​291​​—​​291
Restricted stock unit tax withholding, net of stock option exercises451,471​—​​4,553​​—​—​4,553
Stock-based compensation—​—​​34,923​​—​—​34,923
Balance as of September 30, 202557,596,358​$1​$696,348​$357​$138,417​$835,123

The* *accompanying notes are an integral part of the unaudited condensed consolidated financial statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.